Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05929807




Registration number
NCT05929807
Ethics application status
Date submitted
6/06/2023
Date registered
3/07/2023
Date last updated
16/04/2024

Titles & IDs
Public title
A Clinical Trial to Investigate Long-term Safety, Tolerability, and Efficacy of Weekly Subcutaneous Doses With TransCon CNP in Children and Adolescents With Achondroplasia
Scientific title
A Phase 2, Multicenter, Long-Term, Open Label Extension Trial Evaluating Safety, Tolerability, and Efficacy of Subcutaneous Doses of TransCon CNP Administered Once Weekly in Children and Adolescents With Achondroplasia
Secondary ID [1] 0 0
ASND0039
Universal Trial Number (UTN)
Trial acronym
AttaCH
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Achondroplasia 0 0
Condition category
Condition code
Human Genetics and Inherited Disorders 0 0 0 0
Other human genetics and inherited disorders
Musculoskeletal 0 0 0 0
Other muscular and skeletal disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - TransCon CNP

Experimental: TransCon CNP 100 mcg - TransCon CNP 100 mcg delivered once weekly by subcutaneous injection


Treatment: Drugs: TransCon CNP
TransCon CNP drug product is a lyophilized powder in a single-use vial. Prior to use, the lyophilized powder is reconstituted with sterile water for injection and administered by subcutaneous injection via syringe and needle.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Safety and Tolerability
Timepoint [1] 0 0
Through trial completion, an average of 10 years
Primary outcome [2] 0 0
Height Z-scores
Timepoint [2] 0 0
Through trial completion, an average of 10 years
Secondary outcome [1] 0 0
Annualized Growth Velocity
Timepoint [1] 0 0
Through trial completion, an average of 10 years

Eligibility
Key inclusion criteria
- Written, signed informed consent of the parent(s) or legal guardian(s) of the
participant, and as required by the institutional review board/human research ethics
committee/independent ethics committee (IRB/HREC/IEC). For participants who are below
the age of consent, a written assent will be obtained in accordance with applicable
requirements as required by IRB/HREC/IEC. Upon reaching the legal age of consent,
depending on applicable requirements, these participants will be asked to give their
own written consent.

- Participants with achondroplasia who have completed a clinical trial with TransCon
CNP.

- Parent(s)/legal guardian(s) willing and able to administer weekly SC injections of
TransCon CNP and to follow the protocol.

- Considered eligible based on the safety evaluations performed for evaluating
stopping/holding rule criteria during the prior TransCon CNP clinical trial.
Minimum age
3 Years
Maximum age
15 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Known or suspected hypersensitivity to the investigational product or related products
(trehalose, tris[hydroxymethyl]aminomethane, succinate, and methoxy polyethylene
glycol [mPEG]).

- Have received any dose of prescription medications, investigational medicinal product
(other than TransCon CNP).

- Sexually active female participants and female partners of male participants of
childbearing potential not using a highly effective form of contraceptive (including
oral, injectable, or implantable contraception, or intrauterine device (IUD)) for the
entire trial period and for 90 days post end of the trial.

- Participants with serum 25-hydroxy-vitamin D (25OHD) levels of <50 nmol/L (<20 ng/mL)
at Visit 1 must be on treatment regimen of Vitamin D supplementation.

- Any disease or condition that, in the opinion of the investigator, may make the
participant unlikely to fully complete the trial, may confound interpretation of trial
results, or may present undue risk from receiving trial treatment. This could include
family situations, complications or manifestations, or medications that might impact
safety or be considered confounding.

Study design
Purpose of the study
Treatment
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 2/Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
21/06/2023
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/03/2039
Actual
Sample size
Target
140
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
Ascendis Pharma Investigational Site - Parkville
Recruitment postcode(s) [1] 0 0
3052 - Parkville
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arkansas
Country [2] 0 0
United States of America
State/province [2] 0 0
Colorado
Country [3] 0 0
United States of America
State/province [3] 0 0
Minnesota
Country [4] 0 0
United States of America
State/province [4] 0 0
Montana
Country [5] 0 0
United States of America
State/province [5] 0 0
New York
Country [6] 0 0
United States of America
State/province [6] 0 0
Texas
Country [7] 0 0
United States of America
State/province [7] 0 0
Wisconsin
Country [8] 0 0
Austria
State/province [8] 0 0
Linz
Country [9] 0 0
Denmark
State/province [9] 0 0
Copenhagen
Country [10] 0 0
Germany
State/province [10] 0 0
Berlin
Country [11] 0 0
Ireland
State/province [11] 0 0
Dublin
Country [12] 0 0
New Zealand
State/province [12] 0 0
Auckland

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Ascendis Pharma Growth Disorders A/S
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
TransCon CNP administered once-weekly in children and adolescents with achondroplasia who
have completed a prior TransCon CNP clinical trial. Participants who complete a prior
TransCon CNP trial and meet all eligibility criteria will be invited to continue into the
long-term open label extension trial to receive 100 µg CNP/kg/week of TransCon CNP. Trial
treatment will be completed when the participant reaches 16 years of age for females and 18
years of age for males and have femur and tibial epiphyseal closure. TransCon CNP treatment
will continue if femur and tibial epiphyseal closure is not confirmed at the age of 16 years
for females, and 18 years for males. Treatment with TransCon CNP will be completed once femur
and tibial epiphyseal closure is confirmed by radiographic imaging. The trial duration is
individual for each trial participant. Visits will occur every 12-14 weeks throughout the
trial.
Trial website
https://clinicaltrials.gov/ct2/show/NCT05929807
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Vibeke Breinholt
Address 0 0
Ascendis Pharma
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT05929807